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Infantile spasms can have irrecoverable adverse effects on a child’s 
brain. Adrenocorticotropic hormone (ACTH) is the most common 
first-line medication for the treatment of infantile spasms. However, 
the suitable dose and duration of treatment continue to be debated 
among specialists. Since high doses of ACTH, which are commonly 
used, can produce more side effects, lower doses are preferred. 
The aim of this study was to determine the effect and extent of 
complications caused by high and low doses of ACTH in children 
with infantile spasms.
Materials & Methods 
This clinical trial was performed on 32 infants with infantile spasms, 
aged 1.5-18 months. The subjects were divided into high- and low-
dose ACTH groups. Treatment continued for two months. The 
therapeutic effects and complications were then compared over 18 
months.
Results 
The results indicated no significant difference between the groups in 
terms of the short-term prognosis of convulsions, final prognosis of 
patients with spasm relapse, EEG changes after treatment, and post-
treatment development of hypertension. On the other hand, there was 
a significant difference in the frequency distribution of restlessness 
intensity and becoming Cushingoid, which were more frequent in the 
high-dose group.
Conclusion
The results indicated that high- and low-dose ACTH are equally 
effective in controlling spasms, yet the low dose causes fewer side 
effects.
Keywords: Infantile spasms; ACTH therapy; High-dose treatment; 
Low-dose treatment; Side effects
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Introduction
Infantile spasms are one of the most common 
convulsive syndromes in childhood (1-3). Children 
who are diagnosed with these spasms are within 
the age range of two months to less than one year 
(4, 5). The peak incidence of these spasms occurs 
between three and seven months (50-77%), and 
occurrence is rare after 18 months of age (6). In half 
of patients, cognitive development is normal until 
the onset of convulsions, while cognitive delay has 
been observed in others (7, 8). The approximate 
incidence of this condition is 2-5 infants out of 
every 10,000 successful births (9). Infantile spasms 
at older age evolve into Lennox-Gastaut syndrome; 
therefore, this epileptic pattern is not observed at 
older age (10). Etiologically, these convulsions are 
categorized into symptomatic, crypto-genetic, and 
idiopathic (11, 12). 
In terms of diagnostic measures, a complete awake 
and asleep electroencephalography (EEG) can 
detect the presence of hypsarrhythmia in 50-75% 
of cases as very high and low voltage waves across 
all cortical regions (13-15). Magnetic resonance 
imaging (MRI) is also helpful in diagnosing 
intracerebral lesions, which can predispose an 
infant to infantile spasms (16). Mental retardation 
occurs in 75% of afflicted infants and cerebral 
palsy in 50% (17). Statistically, five out of every 
100 children with infantile spasms do not survive 
for more than five years (18). Less than half of 
patients with infantile spasms do not experience 
any attacks using medications (12). Diagnosis of 
infantile spasms, especially the cryptogenetic and 
idiopathic types, is a medical emergency, as delay 
in diagnosis for three weeks or longer affects the 
long-term prognosis (19). Therapeutically, various 
agents are used, but no medication has proven to 
be 100% effective so far. 
Corticosteroids are the most common form 
of treatment for infantile spasm, with 
adrenocorticotropic hormone (ACTH) being the 
first-line medication (20, 21). Vigabatrin is the 
first-line medication for children with tuberous 
sclerosis and infantile spasms (22). There are 
controversies regarding the suitable dose and 
duration of treatment using ACTH among 
specialists. Since high doses of this drug, which 
are commonly used, cause more side effects, lower 
doses are preferred (23, 24). The aim of this study 
was to determine the effects and side effects of 
high- and low-dose ACTH treatments in children 
with infantile spasms.
Materials & Methods
The subjects were selected among 1.5- to 
18-month-old infants with infantile spasms, who 
were referred to the pediatric neurological clinic 
of Besat Hospital in Hamadan, Iran since October 
20, 2013. A total of 32 infants were included in 
the study and categorized into two equal groups. 
The inclusion criteria were a clinical diagnosis of 
infantile spasms, no use of antiepileptic drugs to 
treat the infantile syndrome, and family consent to 
participate in the program. The exclusion criteria 
were an altered preliminary diagnosis and lack of 
patient cooperation. 
The therapeutic protocol was as follows. Patients 
in the high-dose group received intramuscular 
(IM) injections of 0.25 mg of ACTH. The low-dose 
group received IM injections of 0.1 mg of ACTH. 
ACTH was administered as follows: week 1: once 
a day; week 2: once every other day; week 3: twice 
a week; week 4: once a week; and week 5-8: once 
every two weeks. 
The patients were assigned to one of the groups 
through single-blind block randomization 
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sampling. None of the patients had received 
ACTH treatment before this study. Patients who 
had been recently diagnosed with infantile spasms 
were randomly included in one of the groups 
and received ACTH treatment without delay. 
All patients were hospitalized for seven days for 
medical and neural examinations and monitoring 
the vital signs and blood pressure. Treatment was 
initiated according to the study protocol with either 
a high or low dose of ACTH after advising the 
family and collecting the signed consent forms. 
Initial testing for electrolytes was also performed 
for all patients. Metabolic and other specialized 
tests were performed if required. In addition, 
EEGs and CT scans or MRIs were conducted for 
all patients. Measurement of blood pressure and 
neurological examinations were performed during 
hospitalization on a daily basis. After discharge 
from the hospital, the patients were examined once 
every two weeks for drug side effects. 
In the first, second, and fourth weeks and after 
treatment termination, EEGs were carried out, 
and any changes were recorded as normal (mild), 
moderate, or severe (hypsarrhythmia). At the 
beginning and end of treatment, development 
was examined in the patients and recorded as 
normal development, mild developmental delay, 
or severe developmental delay. To collect data, a 
checklist was prepared at baseline on the patients’ 
characteristics and treatment-associated variables 
at each stage. Information was recorded carefully. 
Response to treatment was classified as complete 
treatment (complete absence of convulsions) 
or relative response to treatment (reduction of 
spastic convulsions by 50% or more compared 
to the onset of treatment). Three variables were 
examined as factors affecting prognosis, including 
developmental changes, relapse of spasms or 
convulsions, and death of patients. In terms of 
EEG, improvement was considered to be the 
absence of hypsarrhythmia. Data were analyzed 
in SPSS version 20 using descriptive (frequency, 
percentage, mean, and standard deviation) and 
inferential (independent sample t-test and Fisher’s 
exact test) statistics. The significance level was 
considered to be 0.05.
Results
In this study, 32 patients were investigated during 18 
months. No patient was excluded during the study. 
Both groups included the same number of patients. 
In terms of gender, it was found that infantile 
spasms were slightly more frequent in boys (56%). 
The mean and standard deviation of infants’ age in 
the high-dose and low-dose groups were 8.2±2.6 
and 5.2±6.6 months, respectively. The results of 
t-test indicated a significant difference in the mean 
age of the groups, but no significant difference 
was found in the onset of infantile spasms or 
onset of treatment between the two groups. The 
results of t-test indicated no significant difference 
regarding the type of infantile spasm (cryptogenic 
or symptomatic) between the groups.
The results of this study showed that patients with 
infantile spasms had a mean age of four months. On 
average, they were diagnosed and treated after about 
two months of delay from the onset of symptoms. 
In terms of clinical type, 59% of the patients were 
categorized as flexor, 28% as extensor-flexor, and 
13% as extensor. Etiologically, 25 (78%) patients 
had the symptomatic disease, and its prevalence 
was not significantly different between the groups. 
The brain imaging results (MRI or CT) showed 
that 53% of the patients had positive findings, with 
the most common imaging findings being cerebral 
atrophy, periventricular leukomalacia, cerebral 
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dysgenesis, and calcification of the basal ganglia. 
During six months of treatment, the patients were 
not significantly different regarding the time and 
duration of hospitalization. Cause of hospitalization 
was the incidence of severe side effects, such as 
hypertension, severe restlessness, infection, or 
relapse of convulsions with inability to control 
them. No significant difference was observed in 
the clinical response to treatment and control of 
convulsions (P=0.16). In 81% of patients, spasms 
were controlled during the first week of treatment; 
the difference was not significant between the 
groups (P=0.16). 
Three out of 32 patients died during 18 months 
of the study (mortality rate=9.4%), all of whom 
belonged to the high-dose ACTH group. Two 
patients experienced asphyxia (hypoxic ischemic 
encephalopathy) and developed severe aspiration 
pneumonia and respiratory distress. One of the 
patients was a child with Down’s syndrome and 
infantile spasms, who died due to sepsis. Although 
these three patients were in the high-dose group, the 
frequency of death was not significantly different 
between the groups (P=0.1). 
There was no significant difference in development 
after treatment (P=0.28). By the end of the 
therapeutic protocol, spasms and convulsions were 
completely controlled in 18.7% of patients without 
any need for further medications. In 5.37% of 
patients, in addition to ACTH, another drug was also 
used to control the convulsions completely. In 25% 
of patients, spasms and convulsions were relatively 
controlled with the addition of another drug. In 
3.9% of patients, despite concurrent treatment 
with ACTH and several other medications, spasms 
and convulsions were resistant to treatment. No 
significant difference was observed in neither of 
four levels defined for controlling convulsions and 
spasms. 
There was no significant difference in the time 
required to control the convulsions. The results 
indicated that there was a significant difference in 
EEG recordings before and after treatment. The 
findings showed that 43% of patients in the low-
dose group and 56% of patients in the high-dose 
group experienced diminished EEG intensity after 
treatment. Irrespective of drug dose, treatment 
with ACTH was clearly effective in improving 
the EEG results (P=0.008) (Table 1). There was 
no significant difference in EEG changes after 
treatment between the groups. There was also 
no significant difference in the incidence of 
hypertension throughout the treatment (P=0.5). On 
the other hand, there was a significant difference 
in the incidence of restlessness and the associated 
sleep disorders (P=0.002). There was also a 
significant difference in terms of the incidence of 
becoming Cushingoid (P=0.04).
21
Comparison of the Effect of High and Low Doses of Adrenocorticotropic Hormone (ACTH) 
Iran J Child Neurol. Spring  2020 Vol. 14 No. 2
Table 1. Frequency distribution of treatment groups with ACTH in terms of electroencephalography (EEG) status before and after 
treatment
EEG changes
Before treatment After treatment
Frequency Percentage Frequency Percentage
Normal 0 0 9 28.1
Mild changes 12 37.5 13 40.6
Severe changes 20 62.5 10 31.3
Total 32 100 32 100
Table 2. Frequency distribution of seizure control and spasm in infants at the onset of treatment 
Days Weeks Without control
Low-dose ACTH 15 1 0
High-dose ACTH 11 3 2
Table 3. Frequency distribution of treatment groups with high- and low-dose ACTH according to the state of development after treat-
ment
Normal Developmental delay
Low-dose ACTH 3 13
High-dose ACTH 1 15
Table 4. Distribution of seizure outcomes and relapse in infants after treatment 
Control with 
ACTH
Control with other 
medications
Relative control Relapse Death
Low-dose ACTH 4 7 3 2 0
High-dose ACTH 2 5 5 1 3
Discussion
Previous studies have shown that use of high-dose 
ACTH is associated with more side effects and 
less desirable therapeutic outcomes, compared to 
its lower doses (25-27). The present study was 
conducted to investigate the therapeutic effects of 
high- and low-dose ACTH on the management of 
infantile spasms in Iranian children. The results 
of the present study showed that high- and low-
dose ACTH were equally effective in controlling 
spasms. The spasms were controlled in about 
81% of patients during the first week of therapy. 
During the follow-up, about 80% of controlled 
cases experienced secondary convulsive relapses, 
but this was not significantly different between the 
groups. 
In a study by Hrachovy et al. (1994), 13 out of 30 
patients treated with high-dose therapy experienced 
complete cessation of spasms, and of 29 participants 
treated with low-dose therapy, 14 experienced 
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complete cessation of spasms (25). In a study by 
Yanagaki et al. (1999), 11 out of 13 patients treated 
with high-dose ACTH and 9 out of 13 patients 
treated with low-dose ACTH experienced spasm 
cessation (26). These two studies revealed that 
high-dose ACTH ended the spasms in 79.5% of 
patients versus 76.5% of patients with low-dose 
ACTH. There was no significant difference in 
terms of relapse rate between the two groups (14). 
Moreover, in a study by Zeng et al. (2011), there 
was a trend towards more complete cessation of 
spasms in the low-dose ACTH group, although the 
difference was not statistically significant. Relapse 
was more frequent in the low-dose ACTH group, 
but no significant difference was found between 
the groups (28).
Response to treatment and final prognosis 
of development were better in patients with 
cryptogenetic infantile spasms, which is consistent 
with the results of previous studies (29). In terms of 
gender distribution, it was observed that infantile 
spasm is slightly more frequent in boys, which is 
in line with the results of most previous studies 
(25, 30). This phenomenon can be attributed to the 
presence of a genetic predisposition, including the 
ARX gene in boys, which is related to the higher 
percentage of male patients. 
The results showed that patients in both groups 
experienced infantile spasms at the mean age of 
about four months. They were diagnosed and 
treated after about two months of delay. This delay 
has been also observed in other studies and is 
associated with vague symptoms of the disease for 
families and general practitioners. EEG changes 
after treatment in both groups suggest that ACTH 
improved the EEG quality in infantile spasms, 
although different drug doses did not affect the 
extent of changes between the groups; this finding 
is in accordance with the results of previous studies 
(26, 27, 31). In this regard, Zeng et al. (2011) found 
no significant difference in the disappearance of 
hypsarrhythmia between the high-dose and low-
dose groups (28).
The present results revealed that there was a 
significant difference between the groups in 
terms of the incidence of hypertension. There was 
also a significance difference in the incidence of 
restlessness and the associated sleep disorders. 
Based on the findings, 83% of patients, who 
experienced severe restlessness and visited a 
physician, belonged to the high-dose ACTH group. 
There was also a significant difference in becoming 
Cushingoid between the groups, with more high-
dose patients becoming Cushingoid. There was 
no significant difference between the groups 
regarding the time and duration of hospitalization 
six months after the initiation of treatment. About 
90% of patients showed further development of the 
disorder by the end of the follow-up, which was 
similar in both groups. Three patients died during 
treatment, all of whom belonged to the high-dose 
ACTH group with symptomatic spasms. Although 
these three patients belonged to the high-dose 
group, the difference in death frequency was not 
significant between the groups.
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In conclusion
the results indicated that high- and low-dose ACTH 
are equally effective in controlling spasms. Lower 
doses of ACTH did not result in the further relapse 
of convulsions, but it was found that use of higher 
doses increased the incidence of side effects. Lack 
of difference in the therapeutic outcomes between 
the groups, along with the reduction of side effects 
in the low-dose group, justifies the use of low-dose 
ACTH for controlling infantile spasms.
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